NEO NEOGENOMICS INC
Services-Testing Laboratories · Nasdaq · SEC CIK 1077183 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.1%
TTM net income YoY71.5%
TTM EPS YoY71.6%
Revenue 3-yr CAGR11.1%
Net income 3-yr CAGR—
Margins
Gross margin44.8%
Operating margin-6.3%
Net margin-4.1%
FCF margin-3.6%
EBITDA margin-1.9%
Returns
ROE-3.9%
ROA-2.3%
ROIC (approx.)-4.6%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets41.9%
Debt / equity0.47x
Current ratio3.53x
Interest coverage-15.21x
Cash quality & payout
Operating cash flow / net income-0.13x
Accruals ratio-2.7%
Payout ratio—
Capex / revenue4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $727.33M | $660.57M | $591.64M | $509.73M | $484.33M |
| Cost of revenue | $413.04M | $370.47M | $347.04M | $321.83M | $297.27M |
| Gross profit | $314.29M | $290.10M | $244.60M | $187.90M | $187.06M |
| R&D expense | $37.08M | $31.16M | $27.31M | $30.33M | $21.87M |
| SG&A expense | $273.34M | $259.74M | $243.10M | $243.36M | $221.35M |
| Operating income | -$115.88M | -$92.11M | -$107.74M | -$157.62M | -$118.75M |
| Interest expense | $3.75M | $6.62M | $6.91M | $7.58M | $8.22M |
| Pretax income | -$110.27M | -$80.67M | -$97.10M | -$159.34M | -$15.07M |
| Income tax | -$2.24M | -$1.95M | -$9.13M | -$15.09M | -$6.73M |
| Net income | -$108.03M | -$78.73M | -$87.97M | -$144.25M | -$8.35M |
| EBITDA | -$79.81M | -$53.01M | -$70.29M | -$122.25M | -$88.56M |
| EPS (diluted) | — | — | — | — | — |
| Weighted avg. shares (diluted) | 128.10M | 126.66M | 125.50M | 124.22M | 119.96M |
| Balance sheet | |||||
| Cash & equivalents | $159.62M | $367.01M | $342.49M | $263.18M | $316.83M |
| Short-term investments | — | — | — | — | $198.56M |
| Receivables | $159.24M | $150.54M | $131.23M | $119.71M | $112.13M |
| Inventory | $28.57M | $26.75M | $24.16M | $24.28M | $23.39M |
| Current assets | $376.29M | $596.02M | $596.81M | $605.29M | $681.51M |
| PP&E, net | $84.83M | $94.10M | $92.01M | $102.50M | $109.47M |
| Goodwill | $524.34M | $522.77M | $522.77M | $522.77M | $527.12M |
| Intangibles | $286.53M | $339.68M | $373.13M | $408.26M | $442.32M |
| Total assets | $1.36B | $1.64B | $1.68B | $1.74B | $1.87B |
| Current liabilities | $88.30M | $301.24M | $96.30M | $89.93M | $87.23M |
| Short-term debt | $0 | $200.78M | $0 | $70,000 | $1.14M |
| Long-term debt | $341.86M | $340.33M | $538.20M | $535.32M | $532.55M |
| Total debt | $341.86M | $541.11M | $538.20M | $535.39M | $533.69M |
| Total liabilities | $523.27M | $735.70M | $739.69M | $742.01M | $761.50M |
| Shareholders' equity | $836.56M | $902.34M | $941.54M | $998.02M | $1.11B |
| Net debt | $182.24M | $174.10M | $195.71M | $272.21M | $216.86M |
| Shares outstanding | 128.99M | 128.15M | 127.37M | 126.91M | 124.11M |
| Cash flow statement | |||||
| Operating cash flow | $5.23M | $7.02M | -$1.95M | -$65.99M | -$26.72M |
| Capital expenditure | $27.01M | $41.06M | $28.75M | $30.89M | $64.14M |
| Free cash flow | -$21.78M | -$34.04M | -$30.70M | -$96.88M | -$90.86M |
| Investing cash flow | -$12.34M | $12.86M | $76.71M | $517,000 | -$632.37M |
| Financing cash flow | -$200.29M | $4.65M | $4.55M | $11.83M | $725.28M |
| Depreciation & amortization | $36.07M | $39.10M | $37.45M | $35.37M | $30.19M |
| Stock-based compensation | $41.32M | $33.41M | $24.63M | $24.67M | $22.46M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.